| Model Number |
40021 |
| Medical Device Problem Code |
Calcified (1077)
|
| Health Effect - Clinical Code |
Calcium Deposits/Calcification (1758)
|
| Date of Event |
01/30/2026
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
It was reported that 4 years and 7 months post implant of this 21mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was not reported.Evidence of calcification was seen in the the left ventricular outflow tract (lvot) under right coronary cusp (rcc), left coronary cusp (lcc) and non-coronary cusp (ncc).No intervention or adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
It was reported that 4 years and 7 months post implant of this 21mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was not reported.Evidence of calcification was seen in the the left ventricular outflow tract (lvot) under right coronary cusp (rcc), left coronary cusp (lcc) and non-coronary cusp (ncc).No intervention or adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Event was incorrectly assessed as serious injury reportable when the initial regulatory report was sent.Per correction this event should be malfunction reportable.B1, b2, h1 and imf (annex f) corrected and updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Per additional information received this event now becomes serious injury reportable with intervention performed on (b)(6) 2026.B1, b2, b5, h1 and imf (annex f) codes updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information received reported on (b)(6) 2026 the patient successfully had a 23mm aortic transcatheter valve-in-valve replacement.No additional adverse patient effects were reported.
|
| |
|
Search Alerts/Recalls
|